The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?…

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer out on The Lancet Oncology thelancet.com/journals/lanon… This multicentre retrospective study aimed to compare the prognostic value of PSMA-PET using the PROMISE (PPP) stage against

#sunniforecast investigated whether IPI-NIVO is superior to SOC (mainly TKI single agent) in ncc-RCC subtypes. All pts. had central pathology. IPI-NIVO had superior OS and supports its role in these rare subtypes. The benefit in chRCC was unexpected. PD-L1+ had highest benefits

AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or observation for 1 year. The pembrolizumab group had a median disease-free survival twice as long as the observation group. nej.md/4gh1b9D #ESMO24

☢ UpFrontPSMA "Live #ESMO24": Lutetium-177 PSMA-617 followed by docetaxel improved anti-tumour activity in men with new diagnosis of metastatic hormone-sensitive prostate cancer compared with docetaxel alone, without increased side effects 🔥Hot off the press The Lancet Oncology:

Neoadjuvant chemotherapy plus durvalumab, followed by adjuvant durvalumab after cystectomy, led to event-free survival superior to that with neoadjuvant chemotherapy followed by cystectomy alone. Full NIAGARA trial results: nej.md/4gmAqk3 #ESMO24

Words of Wisdom Wednesday: Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer by Niklas Klümper, Francisco E. Vera Badillo, Markus Eckstein, Boris Hadaschik and Viktor Grünwald Read the full article here: buff.ly/47kxeS9 #UroSoMe #MedTwitter

After 4 years of the GÖTEBORG-2 trial, MRI-targeted biopsy led to less detection of clinically insignificant prostate cancer than systematic biopsy without compromising the detection of cancer that may affect survival. Read the full trial results: nej.md/4ewOjKT

Outstanding presentation by Dr. Jason Efstathiou #ASTRO24 showing no improvement in any outcome with proton therapy for localised prostate cancer compared to photon therapy. Congratulations to all authors! 👏

the study did not show a meaningful difference. DFS was improved in pts with higher risk of recurrence, such as sRCC, PDL1+ or T4. Getting patient populations right is of clinical interest and leads to stronger recommendations in these groups of patients in my daily practice

In patients with muscle-invasive bladder cancer, extended lymphadenectomy did not improve disease-free or overall survival as compared with the standard procedure and was associated with higher morbidity and mortality. Full SWOG S1011 trial results: nej.md/4dBI8UN

Our latest paper on risk stratified prostate cancer testing - TARGET study, a simultaneous evaluation of PRS, PSAd, F/T PSA, phi in a PSA triggered MRI diagnostic pathway + testing different defn of ‘clinical significance’ link.springer.com/10.1186/s12916…

🚀Big News! Excited to share our work “The Interplay of Mutagenesis and ecDNA Shapes Urothelial Cancer Evolution” published in nature! nature.com/articles/s4158…

Delighted to share our latest on #18F_PSMA_PET just published in cool new JU Open Plus! •n=1335 scans from 1220 men •1°: PSMA 96% vs MRI 89% sens. for pros lesions at RP •2°: PSA 0.2-0.49 post RP/RT ➡️ avidity in 57.8% BUT high false +ves (esp ribs) journals.lww.com/juop/fulltext/…

Sharing key takeaways from my #ASTRO2024 presentation! I'm grateful for the support I've received—thank you, @ASTRO, Mass General Cancer Center National Cancer Institute & @Pcfnews. It’s a win for our field that both #ProtonTherapy & #IMRT are equally highly effective for localized #ProstateCancer.

We are very proud that the paper is online! Sincere thanks to our scientific committee and all panellists. Manuscript is open access, please use and distribute it! Hope to see you at the first edition of Advanced Prostate Cancer Consensus Conference Diagnostics Ken Herrmann prof. Stefano Fanti

Happy to share: Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer - ScienceDirect sciencedirect.com/science/articl…

PEACE-1 RT is now published online at The Lancet Some differences with STAMPEDE Key messages: RT to prostate in M1 #prostatecancer 1. improves rPFS but not OS in low volume 2. improves CRPC-FS & reduces serious GU SAE irrespective of volume Full text: thelancet.com/journals/lance…

Please share on/off X! Great learning opportunity for all physicians who diagnose/treat #ProstateCancer “Answer 🔑” = 4 specialists (2 #radonc, 2 #radiology) sat down together to create a reference standard All levels welcome! Share w/trainees ASTRO ARRO UroSoMe

I am leaving X with a sad eye moving on to more reasonable platforms.